Loading...
XJPX
6190
Market cap7mUSD
Jul 10, Last price  
338.00JPY
1D
0.30%
1Q
-25.22%
Jan 2017
-82.21%
IPO
-87.15%
Name

PhoenixBio Co Ltd

Chart & Performance

D1W1MN
XJPX:6190 chart
P/E
9.81
P/S
0.78
EPS
34.46
Div Yield, %
Shrs. gr., 5y
4.68%
Rev. gr., 5y
9.08%
Revenues
1.57b
+1.57%
1,310,000,0001,013,543,0001,324,817,0002,124,051,0001,715,321,0001,541,388,0001,565,532,000
Net income
125m
P
-415,000,000-238,002,000-387,970,000493,329,00026,378,000-445,650,000125,228,000
CFO
69m
P
-12,000,000-101,909,00016,398,000277,491,000-79,307,000-73,000,00068,857,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
IPO date
Mar 18, 2016
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT